Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

nonoinc.ca

Stage

Angel | Alive

Total Raised

$9.77M

Last Raised

$9.77M | 9 yrs ago

About NoNO

NoNO is a private, clinical-stage biotherapeutics company dedicated to the research, development and commercialization of pharmaceuticals for the treatment of common health disorders with unmet needs, including stroke, traumatic brain injury, and pain. NoNO's therapeutic products all stem from fundamental academic research on central nervous system (CNS) biological targets with well-characterized mechanisms. The company has identified three important therapeutic targets and corresponding products: NA-1, a proprietary inhibitor of PSD-95 proteins found in synapses; TRPM7 ion channel antagonists; and inhibitors of Src-ND2 interactions. The company's lead therapeutic, NA-1, has successfully advanced through Phase 1 and Phase 2 trials in the United States and Canada and is being advanced into multiple clinical indications including Acute Ischemic Stroke, Subarachnoid Hemorrhage and procedurally-induced strokes.

NoNO Headquarters Location

4 W 435 399 Bathurst Street

Toronto, Ontario, M5T 2S8,

Canada

416-603-5801 x 5896

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NoNO

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NoNO is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NoNO Patents

NoNO has filed 47 patents.

The 3 most popular patent topics include:

  • Neurotrauma
  • Stroke
  • NMDA receptor antagonists
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/11/2019

5/24/2022

Neurotrauma, Vascular diseases, Stroke, Rare diseases, Syndromes

Grant

Application Date

4/11/2019

Grant Date

5/24/2022

Title

Related Topics

Neurotrauma, Vascular diseases, Stroke, Rare diseases, Syndromes

Status

Grant

Latest NoNO News

28 years of NONO girls, from design to collection

Jun 20, 2022

Nono, courtesy of the brand How do you ensure that you remain relevant as a children's clothing brand? NONO has been around for 28 years and every day the question is asked internally: What is the strength of the brand? How is the brand unique? And how do the collections meet the demand of the customers? Every contribution must matter. Every collection. NONO has continued to switch gears: to keep responding to the trends, without losing its own character and handwriting. That is not easy, but as a result the brand has never become a short hype and have consistently retained both quality and their own face. In the course of time we have seen a lot of creativity: from the nicest harem pants (a hit for seasons!), to indestructible T-shirts and dresses that you can also wear as a skirt... Nono, courtesy of the brand NONO wants every girl to develop their own unique identity. That’s their mission. Head of Design Karlijn Kragting: "NONO wants to be a guiding light for young girls. Not by setting an example or by acting as a teacher or parent, but by being an inspiring facilitator. NONO provides the tools, the incentives and inspiration for their journey of exploration and self expression. Clothes reflect who kids are, what they wear helps them find their place in this world. We believe in their ideas and encourage them to take themselves seriously. We help them develop their own unique personality”. The latest collection of NONO, summer 2023, is already hanging in our showroom. Ready for the upcoming photo shoots and exhibitions. Nono, courtesy of the brand Karlijn: "In this collection you will see that we created a broad framework within which our target group can easily make their own choices. A fun, exciting and creative incentive to express themselves. Coordinated themes and colors ensure this. In addition, kids can experiment with different styles and combinations". Being relevant in a world we live in today also means paying attention to sustainability. NONO is working hard on this topic and more will be explained about it soon. NONO does not shy away from challenges. That keeps them sharp, flexible and conscientious. A real 'comeback kid'..., so you'll soon read more... NONO is part of BRNDWRKS/Jolo Fashion Group and is established in Amsterdam. The NONO summer collection 2023 will be displayed in our showroom starting July 5th. On Sunday, July 3rd, NONO will perform at the Sunday School in the Fabrique in Maarssen (hal de Smederij) and will participate in the Playtime (standno. B20) in Paris from July 2nd til 4th. Nono, courtesy of the brand Promotion Read more about Nono on their brandpage

NoNO Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NoNO Rank

  • Where is NoNO's headquarters?

    NoNO's headquarters is located at 4 W 435 399 Bathurst Street, Toronto.

  • What is NoNO's latest funding round?

    NoNO's latest funding round is Angel.

  • How much did NoNO raise?

    NoNO raised a total of $9.77M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.